(RTTNews) - Merck & Co. (MRK: News ) announced Friday morning that the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended approval of ELONVA, as a treatment in controlled ovarian stimulation in combination with a GnRH antagonist for the development of multiple follicles in women participating in an assisted reproductive technology program.

Merck & Co. rose during the first half hour of trade Friday and took out the highs of the session around mid-afternoon. Shares finished higher by $1.13 at $36.46. The stock has been on an upward trend for over 2 weeks and set its fifth consecutive new high for the year.

Click here to receive FREE breaking news email alerts for Merck & Co Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: contact editorial@rttnews.com